Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis.

摘要: Background  Targeted oncology therapy with inhibitors of epidermal growth factor receptor is associated numerous cutaneous side effects. Acneiform eruptions are the most frequent skin toxicities reported. They may lead to impairment patients’ quality life and sometimes even become severe enough necessitate interruption or cessation therapy. Objective  To assess possible effect topical phytomenadione (vitamin K1) pre-treatment in diminishing extent severity acne-like follicular rash inhibitor therapy. Methods  A series 20 patients colorectal cancer head neck were pre-treated cream (0.05% seven 0.1% 13 patients), starting morning before first infusion cetuximab panitumumab, followed up for development therapy-associated folliculitis. The was prepared from solution added a hydrophilic base, oil water, obtain concentration 0.05% 0.1%. Results  Majority (15 out 20, 75%) experienced only mild, grade I acneiform eruptions. Five (25%) had II rash, which included two three who used cream. Topical well tolerated no abnormalities blood coagulation observed. Conclusions  might useful inhibitor-associated